Sanofi successfully prices EUR 3 billion bond issue
(Thomson Reuters ONE) -
Sanofi successfully prices EUR 3 billion bond issue
Paris, France - September 6, 2016 - Sanofi announces that it has successfully
priced its offering of EUR 3 billion of notes across 3 tranches:
* EUR 1.0 billion Fixed Rate Notes, due January 2020, bearing interest at an
annual rate of 0.0%
* EUR 0.85 billion Fixed Rate Notes, due September 2022, bearing interest at
an annual rate of 0.0%
* EUR 1.15 billion Fixed Rate Notes, due January 2027, bearing interest at an
annual rate of 0.5%
The issue is drawn under the Company's Euro Medium Term Note Programme.
The transaction enables the Company to lower its average cost of debt and extend
the average maturity of its debt.
Sanofi intends to use the net proceeds of the offering for general corporate
purposes.
BNP Paribas and Morgan Stanley acted as Global Coordinators and Bookrunners,
alongside Crédit Agricole CIB, Deutsche Bank, MUFG and Natixis which acted as
Bookrunners for the offering.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in
Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
DISCLAIMER
This communication shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction.
The notes have not been and will not be registered under the Securities Act and
may not be offered or sold within the United States or to, or for the account or
benefit of, U.S. persons except in certain transactions exempt from the
registration requirements of the Securities Act.
This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within the meaning of
section 21 of the Financial Services and Markets Act 2000) may otherwise
lawfully be communicated or cause to be communicated (all such persons together
being referred to as "relevant persons"). The notes are only available to, and
any invitation, offer or agreement to subscribe, purchase or otherwise acquire
such notes will be engaged in only with, relevant persons. Any person who is not
a relevant person should not act or rely on this document or any of its
contents.
No notes have been offered or sold nor will be offered or sold, directly or
indirectly, to the public in France; the prospectus or any other offering
material relating to the notes have not been distributed or caused to be
distributed and will not be distributed or caused to be distributed to the
public in France; such offers, sales and distributions have been and shall only
be made in France to persons licensed to provide the investment service of
portfolio management for the account of third parties or to qualified investors
(investisseurs qualifiés) other than individuals, investing for their own
account, all as defined in Articles L. 411-1, L. 411-2 and D. 411-1 of the
French Code monétaire et financier.
Forward-Looking Statements
Any statements made in this communication that are not statements of historical
fact, including statements about Sanofi's beliefs and expectations are forward-
looking statements and should be evaluated as such. Forward-looking statements
include statements that may relate to Sanofi's plans, objectives, strategies,
goals, future events, future revenues or performance, and other information that
is not historical information. Sanofi does not undertake, and specifically
disclaims, any obligation or responsibility to update or amend any of the
information above except as otherwise required by law.
Additional Information:
This communication is neither an offer to purchase nor a solicitation of any
offer to sell any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.
--------------------------------------------------------------------------------
Contacts:
Media Relations Investor Relations
Laurence Bollack George Grofik
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
PDF:
http://hugin.info/152918/R/2040208/761068.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2016 - 18:57 Uhr
Sprache: Deutsch
News-ID 492969
Anzahl Zeichen: 6250
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi successfully prices EUR 3 billion bond issue"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
